Tetraphase Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Tetraphase Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 1 currently recruiting 12 completed early-phase tilt top decile by trial count

Tetraphase Pharmaceuticals: 13 sponsored US clinical trials, 1 recruiting.

Tetraphase Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 12 completed. 4 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Complicated Intra-abdominal Infections, with 1 trials.

Top-decile sponsor footprint

Tetraphase Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING Phase 2

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

NCT06794541

COMPLETED Phase 1

A Safety and PK Study of IV Eravacycline

NCT03696550

COMPLETED Phase 1

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

NCT03450187

COMPLETED Phase 1

A Phase 1 Safety and PK Study of IV TP-271

NCT03234738

COMPLETED Phase 1

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

NCT03024034

COMPLETED Phase 3

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

NCT03032510

COMPLETED Phase 3

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

NCT02784704

COMPLETED Phase 1

A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271

NCT02724085

COMPLETED Phase 3

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

NCT01978938

COMPLETED Phase 1

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

NCT02135302

COMPLETED Phase 3

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

NCT01844856

COMPLETED Phase 1

Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women

NCT01989949

COMPLETED Phase 2

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

NCT01265784

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 2
Phase 3 4

What is open in the Tetraphase Pharmaceuticals pipeline

1 recruiting of 13 indexed (8% open); 12 completed (92%).

Phase mix: 4 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Complicated Intra-abdominal Infections (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Tetraphase Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Tetraphase Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%2%4%6%8%10% Total trials Recruiting share Tetraphase PharmaceuticalsAdaptimmuneAgennixAkili Interactive LabsAlumisAndrei IagaruBioXcel TherapeuticsCorporal Michael J. Crescenz VA Medical CenterFresenius Medical Care North America
Tetraphase Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Tetraphase Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

What to do with this Tetraphase Pharmaceuticals page

13 registered trials is a research-attention snapshot, not an endorsement of Tetraphase Pharmaceuticals or any single study.

  • 1 of Tetraphase Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Complicated Intra-abdominal Infections is the condition Tetraphase Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Complicated Intra-abdominal Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Tetraphase Pharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.